Practical benefit of [I-123]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease
Practical benefit of [I-123]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease
复制标题
DOI：
10.1007/bf01728311
复制
发表时间：
1997-01-01
期刊：
影响因子：
--
通讯作者：
vanRoyen, EA
中科院分区：
文献类型：
--
作者：
Booij, J;Tissingh, G;vanRoyen, EA
使用[I-123] β-CIT的单光子发射断层扫描（SPET）研究在体内准确评估了帕金森病（PD）中纹状体多巴胺（DA）转运蛋白的丢失。然而，这些研究还表明，纹状体DA转运蛋白含量的充分成像只能在注射[I-123]beta-CIT后20-30 h进行，这不便于常规门诊评价。最近，一种新的配体，N-ω-氟丙基-2 β-甲氧羰基-3 β-（4-碘苯基）托烷（FP-CIT），成为可用于体内成像的DA转运蛋白。已证明[I-123]FP-CIT的更快动力学允许早在注射后3小时就进行充分采集。在本研究中，在两次连续SPET扫描中评估了5例未用药PD患者的纹状体DA转运蛋白丢失，一次使用[I-123] β-CIT（注射后24小时），一次使用[I-123]FP-CIT（注射后3小时）。尾状核和壳核中特异性与非特异性[I-123]FP-CIT摄取的比率始终比[I-123] β-CIT低2.5倍。然而，当患者这些脑区域中两种配体的摄取率表示为健康对照中发现的摄取率的百分比时，数据的降低和变化都是相似的。根据这些发现得出结论，[I-123]FP-CIT似乎与[I-123]beta-CIT一样适用于评估PD中多巴胺能缺陷。[I-123]FP-CIT的更快动力学是一个明显的优势。
Loss of striatal dopamine (DA) transporters in Parkinson's disease (PD) has been accurately assessed in vivo by single-photon emission tomography (SPET) studies using [I-123]beta-CIT. However, these studies have also shown that adequate imaging of the striatal DA transporter content can be performed only 20-30 h following the injection of [I-123]beta-CIT, which is not convenient for routine out-patient evaluations. Recently, a new ligand, N-omega-fluoropropyl-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane (FP-CIT), became available for in vivo imaging of the DA transporter. The faster kinetics of [I-123]FP-CIT have been shown to allow adequate acquisition as early as 3 h following injection. In the present study, loss of striatal DA transporters in five non-medicated PD patients was assessed on two consecutive SPET scans, one with [I-123]beta-CIT (24 h following injection) and one with [I-123]FP-CIT (3 h following injection). The ratios of specific to non-specific [I-123]FP-CIT uptake in the caudate nucleus and putamen were consistently 2.5-fold lower than those of [I-123]beta-CIT. However, when the uptake ratio of both ligands in these brain regions of patients was expressed as a percentage of the uptake ratio found in healthy controls, both the decrease and the variation of the data were similar. It is concluded on the basis of these findings that [I-123]FP-CIT seems as good as [I-123]beta-CIT for the assessment of the dopaminergic deficit in PD. The faster kinetics of [I-123]FP-CIT are a clear advantage.